Opthea Limited (OPT) Stock Analysis
DELISTED
What happened to Opthea Limited (OPT) stock?
Opthea Limited (OPT) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $4.24B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Opthea Limited (OPT). Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing novel therapies for eye diseases, primarily wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Last analyzed: Jun 15, 2026These figures come from statements filed 16 months ago — the most recent this company has published.
Opthea Limited (OPT) Healthcare & Pipeline Overview
Opthea Limited ADR Information Sponsored
Opthea Limited (OPT) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy OPT shares?
No. OPT stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for OPT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before OPT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Opthea Limited. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.